论文部分内容阅读
目的观察腹腔热灌注联合术后FOLFOX4化疗方案治疗进展期胃癌的临床疗效。方法 72例进展期胃癌根治术患者随机分为试验组(38例)和对照组(34例),试验组患者术后即刻行腹腔热灌注化疗,术后4周行FOLFOX4化疗,对照组患者术后4周仅采用FOLFOX4化疗。随访3年,比较两组患者化疗不良反应、3年生存率和复发率。结果两组患者的不良反应及发生率相近,腹膜刺激症状为试验组特异的不良反应。试验组患者3年生存率为60.5%,生存时间为(30.184±1.239)个月;对照组患者3年生存率为41.2%,生存时间为(25.324±1.638)个月,差异有统计学意义(均P<0.05)。对照组患者的复发率为44.1%,显著高于试验组(21.1%,P=0.036)。结论进展期胃癌患者手术后在FOLFOX4化疗基础上联合脂腔热灌化疗能较为有效的预防术后复发,提高患者生存率,且具备较好的临床安全性。
Objective To observe the clinical efficacy of intraperitoneal hyperthermic perfusion combined with FOLFOX4 chemotherapy in the treatment of advanced gastric cancer. Methods 72 patients with advanced gastric cancer undergoing radical operation were randomly divided into experimental group (38 cases) and control group (34 cases). The patients in experimental group were treated with intraperitoneal hyperthermic perfusion chemotherapy immediately after operation and FOLFOX4 chemotherapy 4 weeks after operation. Patients in control group After 4 weeks only FOLFOX4 chemotherapy. The patients were followed up for 3 years. Adverse reactions, 3-year survival rates and recurrence rates were compared between the two groups. Results The two groups of patients with adverse reactions and the incidence of similar peritoneal irritation symptoms for the test group-specific adverse reactions. The 3-year survival rate was 60.5% and the survival time was (30.184 ± 1.239) months in the test group. The 3-year survival rate was 41.2% in the control group and the survival time was (25.324 ± 1.638) months, the difference was statistically significant All P <0.05). The recurrence rate of the control group was 44.1%, significantly higher than that of the test group (21.1%, P = 0.036). Conclusions The combination of FOLFOX4 chemotherapy and intraperitoneal injection of hot intravitreal injection of hot water may be effective in preventing postoperative recurrence and improving the survival rate of patients with advanced gastric cancer after FOLFOX4 chemotherapy, and has good clinical safety.